Cleary, James M. http://orcid.org/0000-0001-7213-3951
Rouaisnel, Betty
Daina, Antoine
Raghavan, Srivatsan http://orcid.org/0000-0002-5374-9918
Roller, Lauren A.
Huffman, Brandon M. http://orcid.org/0000-0002-0768-3145
Singh, Harshabad
Wen, Patrick Y.
Bardeesy, Nabeel
Zoete, Vincent
Wolpin, Brian M.
Losman, Julie-Aurore
Funding for this research was provided by:
AbbVie Inc. | AbbVie Biotherapeutics
Eli Lilly and Company
Bayer
Article History
Received: 20 December 2021
Accepted: 1 August 2022
First Online: 2 September 2022
Competing interests
: J.M.C. receives research funding for his institution from AbbVie, Merus, Roche, and Bristol Myers Squibb. He receives research funding from Merck, AstraZeneca, Esperas Pharma, Bayer, and Tesaro; he received an honorarium for being on the advisory board of Agios, Syros Pharmaceuticals, and Blueprint Medicines. P.Y.W. receives research support from Agios, AstraZeneca/Medimmune, Bayer, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Vascular Biogenics, and VBI Vaccines. He has served on the advisory board of Agios, AstraZeneca, Bayer, Black Diamond, Boston Pharmaceuticals, Elevate Bio, Imvax, Karyopharm, Merck, Mundiphrama, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Vascular Biogenics, VBI Vaccines, Voyager, and QED. V.Z. declares consulting for Cellestia Biotech AG. B.M.W. declares research funding from Celgene and Eli Lilly & Company and consulting for BioLineRx, Celgene, and GRAIL. J.-A.L. laboratory has received research funding from Lilly and Bayer. The remaining authors declare no competing interests.